Takeda/Ovid Broaden Pioneering CH24H Inhibitor To Rare Epilepsies
Takeda and partner Ovid are planning new trials in rare pediatric indications for their first-in-class epilepsy drug, including in the increasingly competitive area of Dravet syndrome.
You may also be interested in...
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
Biocodex's Diacomit – long approved in the EU – just won FDA approval. That brings the number of drugs cleared for Dravet in the US to two, including GW Pharma's recently endorsed Epidiolex, and the R&D pipeline for this rare seizure disorder is growing.